Smith Group Asset Management’s Biohaven Pharmaceutical Holding Company Ltd. BHVN Stock Holding History

Smith Group Asset Management’s Portfolio BHVN Stock Details BHVN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-60	Closed	-$8K	–	378
2021 Q4	$8K	Hold	60	–	–	﹤0.01%	326
2021 Q3	$8K	Hold	60	–	–	﹤0.01%	327
2021 Q2	$6K	Hold	60	–	–	﹤0.01%	340
2021 Q1	$4K	Sell	60 -1,590	-96%	-$129K	﹤0.01%	313
2020 Q4	$141K	Sell	1,650 -10	-0.6%	-$847	0.01%	192
2020 Q3	$108K	Buy	1,660 +520	+46%	+$34.1K	0.01%	195
2020 Q2	$83K	Sell	1,140 -10	-0.9%	-$532	﹤0.01%	199
2020 Q1	$39K	Hold	1,150	–	–	﹤0.01%	254
2019 Q4	$63K	Hold	1,150	–	–	﹤0.01%	267
2019 Q3	$48K	Buy	+1,150	New	+$48.6K	﹤0.01%	280

Other funds holding BHVN

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Allspring Global Investments Charlotte, North Carolina $59.7B AUM 29.08% 1-Year Est. Return

OIM

Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Smith Group Asset Management's BHVN Position: Q1 2022 in Review

Smith Group Asset Management sold out of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) in Q1 2022, closing a stake of 60 shares — an estimated $8K sold.

Smith Group Asset Management first reported a position in BHVN in Q3 2019 and held it in 10 quarters. The position peaked at $141K in Q4 2020. 307 funds tracked by Wall St. Rank hold BHVN as of Q1 2022.

Smith Group Asset Management reported no remaining Biohaven Pharmaceutical Holding Company Ltd. position as of Q1 2022 after selling out during the quarter.
Smith Group Asset Management sold 60 Biohaven Pharmaceutical Holding Company Ltd. shares in Q1 2022, an estimated $8K.
Smith Group Asset Management first reported a position in Biohaven Pharmaceutical Holding Company Ltd. in Q3 2019 and held it in 10 quarters.
Smith Group Asset Management's Biohaven Pharmaceutical Holding Company Ltd. position peaked at $141K in Q4 2020.
307 funds tracked by Wall St. Rank held Biohaven Pharmaceutical Holding Company Ltd. as of Q1 2022.

Based on Smith Group Asset Management's 13F filing for Q1 2022, filed 5 May 2022.